Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study

Table 2 Most recent treatment episode: Hazard ratio of treatment discontinuation

	Cox Model Hazard Ratio ^a (95% confidence interval) ^b
	15-day gap n = 66,576	30-day gap n = 59,441	60-day gap n = 45,125
Erenumab	1.32 (1.19, 1.49)	1.26 (1.11, 1.44)	1.19 (1.02, 1.40)
Fremanezumab	1.58 (1.42, 1.80)	1.53 (1.34, 1.75)	1.42 (1.22, 1.66)
Galcanezumab	1.42 (1.27, 1.61)	1.35 (1.19, 1.53)	1.26 (1.08, 1.47)
OnabotulinumtoxinA	0.98 (0.87, 1.10)	0.98 (0.87, 1.12)	1.02 (0.87, 1.18)
Eptinezumab	Reference	Reference	Reference

^aAdjusted for all covariates (including age, sex, insurance type, migraine type, comorbidities, prescriber, prior anti-CGRP mAb and onabotulinumtoxinA treatment history, history of non–anti-CGRP oral preventives, history of acute medication use, and history of inpatient/outpatient/ER visits)
^bBoot-strapped confidence interval. Note: sample size is reduced since extending the gap period changes the definition of an episode (e.g., distinct episodes with the same drug based on a 15-day gap may become a single episode and is excluded if the episode begins before June 25, 2020)

ISSN: 1129-2377